# Champions Oncology, Inc.: Form 10-Q for the period ended Jan 31, 2016

- Company: [Champions Oncology, Inc.](/companies/csbr.md) (CIK 771856)
- Form: 10-Q
- Filed: 2016-03-16
- Accepted by EDGAR: Mar 16, 2016, 10:01 ET
- Period: 2016-01-31
- Accession: 0001144204-16-088331
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/771856/000114420416088331/v433237_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/771856/000114420416088331/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-01-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2015-11-01 to 2016-01-31 | $999.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2015-05-01 to 2016-01-31 | $3.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2015-11-01 to 2016-01-31 | −$2.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2015-05-01 to 2016-01-31 | −$7.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2015-11-01 to 2016-01-31 | $31.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2015-05-01 to 2016-01-31 | $76.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2015-11-01 to 2016-01-31 | −$2.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2015-05-01 to 2016-01-31 | −$7.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2015-11-01 to 2016-01-31 | −$0.28 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2015-05-01 to 2016-01-31 | −$0.90 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2015-11-01 to 2016-01-31 | −$0.28 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2015-05-01 to 2016-01-31 | −$0.90 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2015-11-01 to 2016-01-31 | 8,702,237 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2015-05-01 to 2016-01-31 | 8,702,237 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 9 months, 2015-05-01 to 2016-01-31 | $176.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2016-01-31 | $3.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-01-31 | $5.8m | us-gaap:AssetsCurrent |
| Total assets | at 2016-01-31 | $7.1m | us-gaap:Assets |
| Current liabilities | at 2016-01-31 | $4.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-01-31 | $4.9m | us-gaap:Liabilities |
| Shareholders' equity | at 2016-01-31 | $2.3m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 14,963 characters.

*The following discussion of our historical results of operations and our liquidity and capital resources should be read in conjunction with the condensed consolidated financial statements and related notes that appear elsewhere in this report and our most recent annual report for the year ended April 30, 2015, as filed on Form 10-K.*

### Forward-Looking Statements

This Quarterly Report on Form 10-Q contains certain “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. These forward-looking statements include, without limitation, statements regarding: proposed new programs; expectations that regulatory developments or other matters will not have a material adverse effect on our financial position, results of operations, or liquidity; statements concerning projections, predictions, expectations, estimates, or forecasts as to our business, financial and operational results, and future economic performance; and statements of management’s goals and objectives and other similar expressions concerning matters that are not historical facts. Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar expressions, as well as statements in future tense, identify forward-looking statements.

Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Forward-looking statements speak only as of the date the statements are made. Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to, those described in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2015, as updated in our subsequent reports filed with the SEC, including any updates found in Part II, Item 1A of this or other reports on Form 10-Q. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

### Overview and Recent Developments

Champions Oncology, Inc. is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is a novel approach to personalizing cancer care, based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related products, to offer solutions for two customer groups:

- Our Personalized Oncology Solutions, or POS, business, which provides services to physicians and patients looking for information to help guide the development of personalized treatment plans.
- Our Translational Oncology Solutions, or TOS, business, which provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development that will lower costs and increase the speed of developing new drugs, as well as increase the adoption of existing drugs.

We plan to continue our efforts to expand our TumorGraft Technology Platform in order to expand our POS and TOS programs.

### Liquidity and Capital Resources

Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements, and other strategic initiatives. In the past, we have met these cash requirements through our sales of products and services, cash and cash equivalents, working capital management, and proceeds from certain private placements of our securities. As of January 31, 2016, we had positive working capital of $1.2 million and cash and cash equivalents on hand of $3.3 million. We believe that our cash and cash equivalents on hand at January 31, 2016 are adequate to fund our operations through at least April 2017. However, in order for us to continue as a going concern beyond this point, we may need to obtain capital from external sources. If we are unable to obtain additional financing, we may be required to reduce the scope of, or delay or eliminate, some of our research and development and other activities, which could harm our financial condition and operating results. Financing may not be available on acceptable terms or at all, and our failure to raise capital when needed could negatively impact our growth plans and our financial condition and results of operations. Additional equity financing may be dilutive to the holders of our common stock and debt financing, if available, may involve significant cash payment obligations and covenants and/or financial ratios that restrict our ability to operate our business.

### Operating Results

The following table summarizes our operating results for the periods presented below (dollars in thousands):

| Operating revenue: | For the Three Months Ended January 31, 2016 | % of Revenue | 2015 | % of% Revenue | Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| Personalized oncology solutions | $416 | 16.3% | $453 | 24.8% | (8.2)% |
| Translational oncology solutions | 2,136 | 83.7 | 1,376 | 75.2 | 55.2 |
| Total operating revenue | 2,552 | 100.0 | 1,829 | 100.0 | 39.5 |
| **Costs and operating expenses:** |  |  |  |  |  |
| Cost of personalized oncology solutions | 479 | 18.8 | 674 | 36.9 | (28.9) |
| Cost of translational oncology solutions | 1,627 | 63.8 | 1,301 | 71.1 | 25.1 |
| Research and development | 999 | 39.1 | 1,093 | 59.8 | (8.6) |
| Sales and marketing | 779 | 30.5 | 1,094 | 59.8 | (28.8) |
| General and administrative | 1,041 | 40.8 | 1,086 | 59.4 | (4.1) |
| Total costs and operating expenses | 4,925 | 193.0 | 5,248 | 286.9 | (6.2) |
| Operating loss | $(2,373) | (93.0)% | $(3,419) | (186.9)% | (30.6) |

| Operating revenue: | For the Nine Months Ended January 31, 2016 | % of Revenue | 2015 | % of% Revenue | Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| Personalized oncology solutions | $1,387 | 16.6% | $1,245 | 22.1% | 11.4% |
| Translational oncology solutions | 6,958 | 83.4 | 4,377 | 77.9 | 59.0 |
| Total operating revenue | 8,345 | 100.0 | 5,622 | 100.0 | 48.4 |
| **Costs and operating expenses:** |  |  |  |  |  |
| Cost of personalized oncology solutions | 1,661 | 19.9 | 2,190 | 39.0 | (24.2) |
| Cost of translational oncology solutions | 4,683 | 56.1 | 3,225 | 57.4 | 45.2 |
| Research and development | 3,018 | 36.2 | 3,757 | 66.8 | (19.7) |
| Sales and marketing | 2,688 | 32.2 | 3,340 | 59.4 | (19.5) |
| General and administrative | 4,062 | 48.7 | 3,944 | 70.2 | 3.0 |
| Total costs and operating expenses | 16,112 | 193.1 | 16,456 | 292.7 | (2.1) |
| Operating loss | $(7,767) | (93.1)% | (10,834) | (192.7)% | (28.3) |

15

### Operating Revenues

Operating revenues were $2.6 million and $1.8 million for the three months ended January 31, 2016 and 2015, respectively, an increase of $800,000 or 39.5%. Operating revenues were $8.3 million and $5.6 million for the nine months ended January 31, 2016 and 2015, respectively, an increase of $2.7 million or 48.4%.

POS revenues were $416,000 and $453,000 for the three months ended January 31, 2016 and 2015, respectively, a decrease of $37,000, or (8.2%). The decrease is due to a decline of $215,000 in implant and panel revenue offset by an increase of $162,000 in sequencing revenue. POS revenues were $1.39 million and $1.25 million for the nine months ended January 31, 2016 and 2015, respectively, an increase of $140,000, or 11.4%. The increase is the result of growth in our sequencing revenue offset by a decline in implant and panel revenue.

TOS revenues were $2.1 million and $1.4 million for the three months ended January 31, 2016 and 2015, respectively, an increase of $700,000, or 55.2%. TOS revenues were $7 million and $4.4 million for the nine months ended January 31, 2016 and 2015, respectively, an increase of $2.6 million, or 59%. The increase is due to increased bookings, both in the number and size of the studies, in prior quarters due to the expansion of the TOS sales team and growth of the platform.

### Cost of Personalized Oncology Solutions

Cost of POS for the three months ended January 31, 2016 and 2015 were $479,000 and $674,000, respectively, a decrease of $195,000, or (28.9%). Cost of POS for the nine months ended January 31, 2016 and 2015 were $1.7 million and $2.2 million, respectively, a decrease of $500,000 or (24.2%). For the three months ended January 31, 2016 and 2015, gross margins for POS were (15.1%) and (48.8%), respectively. For the nine months ended January 31, 2016 and 2015, gross margins for POS were (19.8)% and (75.9)%, respectively. The improvement in gross margin is attributed to the increase in higher margin, sequencing revenue, and aggressively managing our lab costs.

### Cost of Translational Oncology Solutions

Cost of TOS for the three months ended January 31, 2016 and 2015 were $1.6 million and $1.3 million, respectively, an increase of $300,000, or 25.1%. Cost of TOS for the nine months ended January 31, 2016 and 2015 were $4.7 million and $3.2 million, respectively, an increase of $1.5 million, or 45.2%. For the three months ended January 31, 2016 and 2015, gross margins for TOS were 23.8% and 5.5%, respectively. For the nine months ended January 31, 2016 and 2015, gross margins for TOS were 32.7% and 26.3%, respectively. Gross margins vary quarterly based on timing differences between expense and revenue recognition. The improvement in gross margin was due to higher TOS revenue leveraged off the fixed cost component of the lab and effective management of the variable lab costs.

### Research and Development

Research and development expenses for the three months ended January 31, 2016 and 2015 were $1 million and $1.1 million, respectively, a decrease of $100,000, or (8.6%). Research and development expenses for the nine months ended January 31, 2016 and 2015 were $3 million and $3.8 million, respectively, a decrease of $800,000, or (19.7%). The decrease is due to lower expenses in genomic characterization of our Champions TumorGraft Bank.

### Sales and Marketing

Sales and marketing expenses for the three months ended January 31, 2016 and 2015 were $779,000 and $1.1 million, respectively, a decrease of $321,000, or (28.8%). Sales and marketing expenses for the nine months ended January 31, 2016 and 2015 were $2.7 million and $3.3 million, respectively, a decrease of $600,000, or (19.5%). The decrease is due to the consolidation of the sales and marketing resources of the POS and TOS division, including combining both under one commercial business leader.

### General and Administrative

General and administrative expenses for the three months ended January 31, 2016 and 2015 were $1.04 million and $1.09 million, respectively, a decrease of $50,000, or (4.1%). General and administrative expenses for the nine months ended January 31, 2016 and 2015 were $4.1 million and $3.9 million, respectively, an increase of $200,000, or 3%. The increase is due to an increase in stock based compensation for the President and CEO.

### Other Income (Expense)

Other income (expense) for the three months ended January 31, 2016 and 2015 were ($8,000) and $615,000, a decrease in income of $623,000. Other income (expense) for the nine months ended January 31, 2016 and 2015 were ($29,000) and $1.4 million, a decrease in income of $1.4 million. The change is mainly due to the gain on fair value of warrants that were accounted for as liabilities in during fiscal year 2015 which were reclassified into equity. See the Company’s annual report on Form 10-K, footnote 7, filed on July 29, 2015 for further discussion.

### Inflation

Inflation does not have a meaningful impact on the results of our operations.

### Cash Flows

The following discussion relates to the major components of our cash flows:

#### Cash Flows from Operating Activities

Net cash used in operating activities were $5.9 million and $7.6 million for the nine months ended January 31, 2016 and 2015, respectively, a decrease of $1.7 million. The decrease in net cash used is due to higher revenues and aggressively managing cost.

#### Cash Flows from Investing Activities

Net cash used in investing activities were $175,000 and $84,000 for the nine months ended January 31, 2016 and 2015, respectively. These cash outflows primarily relate to the purchase of property and equipment.

#### Cash Flows from Financing Activities

Net cash (used in)/provided by financing activities were ($35,000) and $2 million for the nine months ended January 31, 2016 and 2015, respectively. The cash outflows in 2016 relate to issuance costs for a 2015 private placement and capital lease payments as compared to a significant capital raise in the prior year.

### Critical Accounting Estimates and Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to apply methodologies and make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates of the Company include, among other things, accounts receivable realization, revenue recognition (replacement of licensed tumors), valuation allowance for deferred tax assets, valuation of goodwill, and stock compensation and warrant assumptions. Actual results could differ from those estimates. The Company’s critical accounting policies are summarized in the Company’s Annual Report on Form 10-K, filed with the SEC on July 29, 2015.

### Off-Balance Sheet Financing

We have no off-balance sheet debt or similar obligations. We have no transactions or obligations with related parties that are not disclosed, consolidated into or reflected in our reported results of operations or financial position. We do not guarantee any third-party debt.

## Controls and procedures

As filed, 1,604 characters.

### Evaluation of Disclosure Controls and Procedures

It is management’s responsibility to establish and maintain “disclosure controls and procedures” as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. Our management, with the participation of our Chief Executive Officer and our Vice President, Finance, have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this quarterly report. Based on that evaluation, our management, including our Chief Executive Officer and our Vice President, Finance, have concluded that our disclosure controls and procedures were effective as of January 31, 2016 at the reasonable assurance level in ensuring that information required to be disclosed in the reports that we file or submit under the Securities Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and our Vice President, Finance, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting in connection with the evaluation required by Rule 13a-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 2,396 characters.

**We may not be able to meet our cash requirements beyond April 2017 without reducing the scope of our activities or obtaining additional capital from external sources, and if we are unable to do so, we may not be able to continue as a going concern.**

As of January 31, 2016, we had working capital of $1.2 million and cash and cash equivalents of $3.3 million. We believe that our cash and cash equivalents on hand at January 31, 2016 are adequate to fund our operations through at least April 2017. However, in order for us to continue as a going concern beyond this point, we may need to reduce the scope of our activities or obtain capital from external sources.

We have generated net losses for our past recent history. For the years ended April 30, 2015 and 2014, the Company had a net loss of approximately $13.1 million and $7.4 million, respectively, and for the nine months ended January 31, 2016, we had a net loss of $7.9 million. We will not be able to continue as a going concern without additional financing. Even if we do raise sufficient capital to support our operating expenses beyond April 2017, there can be no assurances that the proceeds raised will be sufficient to enable our business to reach a level where it will generate profits from operations. Currently, the Company derives revenue from POS products and TOS products, while pursuing efforts to further develop bioinformatics from its TumorBank and its TumorGraft Technology Platform. In addition, we are building our sales and marketing operations to grow our TOS and POS products. Accordingly, we expect to generate operating losses in the future until such time as we are able to generate significantly more revenue.

If we are unable to obtain additional financing, we may be required to reduce the scope of, or delay or eliminate, some of our research and development and other activities, which could harm our financial condition and operating results. Financing may not be available on acceptable terms or at all, and our failure to raise capital when needed could negatively impact our growth plans and our financial condition and results of operations. Additional equity financing may be dilutive to the holders of our common stock and debt financing, if available, may involve significant cash payment obligations and covenants and/or financial ratios that restrict our ability to operate our business.

Filed Mar 16, 2016.
Source: SEC EDGAR, the filing index for accession 0001144204-16-088331. Last ingested by Listed: Nov 10, 2026, 03:33 ET. No prices; not investment advice.
